FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016082045> ?p ?o ?g. }

• W2016082045 abstract "Cisplatin is the most important drug in the treatment of advanced ovarian cancer. The role of anthracyclines is controversial. We compared a combination of epirubicin plus cisplatin (EP) with a regimen of cyclophosphamide, epirubicin and cisplatin (CEP). Patients with stage Ic-IV ovarian cancer were randomized to receive either epirubicin 100 mg/m2 plus cisplatin 75 mg/m2 q 4 weeks or cyclophosphamide 500 mg/m2 plus epirubicin 75 mg/m2 plus cisplatin 50 mg/m2 q 4 weeks, which we considered the reference treatment based on our previous experience. Patients were initially debulked, followed by six cycles of chemotherapy, or in case primary debulking was insufficient or considered inappropriate, secondary debulking was attempted in selected cases after sufficient chemotherapy-induced regression. Optimal debulking was defined as residual lesions < or = 2 cm. A total of 210 patients (191 eligible) were randomized. Results did not show significant differences in all major endpoints (pathologically documented complete response and survival). The median survival for all patients was 34 months, for patients with stage III 26 months, for patients with stage IV 20 months and it has not been reached for patients with stage Ic-II. As no significant differences between an equitoxic regimen of EP and CEP were detected, it might be more useful to look again at the anthracyclines as part of combination chemotherapy instead of the alkylating agents." @default.
• W2016082045 created "2016-06-24" @default.
• W2016082045 creator A5002072466 @default.
• W2016082045 creator A5006823747 @default.
• W2016082045 creator A5008020237 @default.
• W2016082045 creator A5008199810 @default.
• W2016082045 creator A5012924518 @default.
• W2016082045 creator A5017472555 @default.
• W2016082045 creator A5031740975 @default.
• W2016082045 creator A5034900959 @default.
• W2016082045 creator A5043997587 @default.
• W2016082045 creator A5045872355 @default.
• W2016082045 creator A5046685638 @default.
• W2016082045 creator A5056297990 @default.
• W2016082045 creator A5059450973 @default.
• W2016082045 creator A5062797209 @default.
• W2016082045 creator A5064807039 @default.
• W2016082045 creator A5068929177 @default.
• W2016082045 creator A5069023434 @default.
• W2016082045 creator A5073550666 @default.
• W2016082045 creator A5075279881 @default.
• W2016082045 creator A5086145268 @default.
• W2016082045 creator A5086894799 @default.
• W2016082045 creator A5089650146 @default.
• W2016082045 date "1999-03-01" @default.
• W2016082045 modified "2023-09-26" @default.
• W2016082045 title "Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg" @default.
• W2016082045 doi "https://doi.org/10.1097/00001813-199903000-00001" @default.
• W2016082045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10327029" @default.
• W2016082045 hasPublicationYear "1999" @default.
• W2016082045 type Work @default.
• W2016082045 sameAs 2016082045 @default.
• W2016082045 citedByCount "6" @default.
• W2016082045 countsByYear W20160820452018 @default.
• W2016082045 countsByYear W20160820452021 @default.
• W2016082045 crossrefType "journal-article" @default.
• W2016082045 hasAuthorship W2016082045A5002072466 @default.
• W2016082045 hasAuthorship W2016082045A5006823747 @default.
• W2016082045 hasAuthorship W2016082045A5008020237 @default.
• W2016082045 hasAuthorship W2016082045A5008199810 @default.
• W2016082045 hasAuthorship W2016082045A5012924518 @default.
• W2016082045 hasAuthorship W2016082045A5017472555 @default.
• W2016082045 hasAuthorship W2016082045A5031740975 @default.
• W2016082045 hasAuthorship W2016082045A5034900959 @default.
• W2016082045 hasAuthorship W2016082045A5043997587 @default.
• W2016082045 hasAuthorship W2016082045A5045872355 @default.
• W2016082045 hasAuthorship W2016082045A5046685638 @default.
• W2016082045 hasAuthorship W2016082045A5056297990 @default.
• W2016082045 hasAuthorship W2016082045A5059450973 @default.
• W2016082045 hasAuthorship W2016082045A5062797209 @default.
• W2016082045 hasAuthorship W2016082045A5064807039 @default.
• W2016082045 hasAuthorship W2016082045A5068929177 @default.
• W2016082045 hasAuthorship W2016082045A5069023434 @default.
• W2016082045 hasAuthorship W2016082045A5073550666 @default.
• W2016082045 hasAuthorship W2016082045A5075279881 @default.
• W2016082045 hasAuthorship W2016082045A5086145268 @default.
• W2016082045 hasAuthorship W2016082045A5086894799 @default.
• W2016082045 hasAuthorship W2016082045A5089650146 @default.
• W2016082045 hasConcept C121608353 @default.
• W2016082045 hasConcept C126322002 @default.
• W2016082045 hasConcept C126894567 @default.
• W2016082045 hasConcept C141071460 @default.
• W2016082045 hasConcept C143998085 @default.
• W2016082045 hasConcept C2776694085 @default.
• W2016082045 hasConcept C2776755627 @default.
• W2016082045 hasConcept C2776802502 @default.
• W2016082045 hasConcept C2778239845 @default.
• W2016082045 hasConcept C2780427987 @default.
• W2016082045 hasConcept C2780835546 @default.
• W2016082045 hasConcept C2781100745 @default.
• W2016082045 hasConcept C2781413609 @default.
• W2016082045 hasConcept C530470458 @default.
• W2016082045 hasConcept C71924100 @default.
• W2016082045 hasConceptScore W2016082045C121608353 @default.
• W2016082045 hasConceptScore W2016082045C126322002 @default.
• W2016082045 hasConceptScore W2016082045C126894567 @default.
• W2016082045 hasConceptScore W2016082045C141071460 @default.
• W2016082045 hasConceptScore W2016082045C143998085 @default.
• W2016082045 hasConceptScore W2016082045C2776694085 @default.
• W2016082045 hasConceptScore W2016082045C2776755627 @default.
• W2016082045 hasConceptScore W2016082045C2776802502 @default.
• W2016082045 hasConceptScore W2016082045C2778239845 @default.
• W2016082045 hasConceptScore W2016082045C2780427987 @default.
• W2016082045 hasConceptScore W2016082045C2780835546 @default.
• W2016082045 hasConceptScore W2016082045C2781100745 @default.
• W2016082045 hasConceptScore W2016082045C2781413609 @default.
• W2016082045 hasConceptScore W2016082045C530470458 @default.
• W2016082045 hasConceptScore W2016082045C71924100 @default.
• W2016082045 hasLocation W20160820451 @default.
• W2016082045 hasLocation W20160820452 @default.
• W2016082045 hasOpenAccess W2016082045 @default.
• W2016082045 hasPrimaryLocation W20160820451 @default.
• W2016082045 hasRelatedWork W1966007507 @default.
• W2016082045 hasRelatedWork W2014090721 @default.
• W2016082045 hasRelatedWork W2055272681 @default.
• W2016082045 hasRelatedWork W2400212447 @default.
• W2016082045 hasRelatedWork W2410995755 @default.
• W2016082045 hasRelatedWork W2415703278 @default.
• W2016082045 hasRelatedWork W2423566731 @default.
• W2016082045 hasRelatedWork W2435413466 @default.

• next